Please login to the form below

Not currently logged in
Email:
Password:

motor neurone disease

This page shows the latest motor neurone disease news and features for those working in and with pharma, biotech and healthcare.

AB Science claims first with motor neurone disease therapy

AB Science claims first with motor neurone disease therapy

ALS patients on masitnib lived longer without their disease progressing. French biotech AB Science is celebrating after a pivotal trial of its lead drug masitinib for motor neurone disease hit its ... Masitinib is also in phase III testing for

Latest news

  • PatientsLikeMe launches 'virtual trial' in ALS PatientsLikeMe launches 'virtual trial' in ALS

    PatientsLikeMe has started a small-scale 'virtual trial' to evaluate the potential of a peptide to reverse the symptoms of degenerative motor disorder ALS. ... The online community is working with The Duke ALS Clinical in the US on the study, which will

  • FDA grants orphan drug status to Treeway's ALS treatment FDA grants orphan drug status to Treeway's ALS treatment

    ALS, which is commonly known as Lou Gehrig's disease in the US and as motor neurone disease in certain other countries, causes muscle weakness, disability and eventually death. ... The disease received a major boost in awareness last year due to the ALS

  • Charity coalition pledges millions for brain disease research Charity coalition pledges millions for brain disease research

    The funding will focus on neurodegenerative conditions, such as dementia, motor neurone disease and Parkinson's disease for which there is an unmet need.

  • Pharma takes the ALS Ice Bucket Challenge Pharma takes the ALS Ice Bucket Challenge

    weeks. Evotec's motor neuron researchers performed the ice bucket challenge outside their headquarters in Hamburg after challenging CEO Dr Werner Lanthaler and CSO Cord Dohrmann, who later accepted. ... ALS, which is the most common type of motor neurone

  • Biogen Idec signs brain research deal with Edinburgh University Biogen Idec signs brain research deal with Edinburgh University

    Will identify potential treatments for multiple sclerosis and motor neurone disease. ... US biotech Biogen Idec is to research potential new treatments for the neurodegenerative conditions multiple sclerosis and motor neurone disease in collaboration

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... In fact, this has helped our team of scientists at BenevolentBio establish a set of hypotheses for drug candidates for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Biogen Idec names ALS unit head Biogen Idec names ALS unit head

    ALS, which is commonly known as Lou Gehrig's disease in the US and as motor neurone disease in certain other countries, has received a boost in awareness in recent weeks

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics